• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Responses to SARS-CoV-2 Among Patients With Cancer: What Can Seropositivity Tell Us?

作者信息

Sun Lova, Warner Jeremy L, Parikh Ravi B

机构信息

Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Nashville, Tennessee.

出版信息

JAMA Oncol. 2021 Aug 1;7(8):1123-1125. doi: 10.1001/jamaoncol.2021.2096.

DOI:10.1001/jamaoncol.2021.2096
PMID:34047766
Abstract
摘要

相似文献

1
Immune Responses to SARS-CoV-2 Among Patients With Cancer: What Can Seropositivity Tell Us?癌症患者对SARS-CoV-2的免疫反应：血清阳性能告诉我们什么？
JAMA Oncol. 2021 Aug 1;7(8):1123-1125. doi: 10.1001/jamaoncol.2021.2096.
2
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.癌症患者对 SARS-CoV-2 的预先存在和 COVID-19 后免疫反应。
Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19.
3
Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.SARS-CoV-2 特异性 T 细胞免疫和低过敏毒素水平与 COVID-19 患者的轻度疾病进展相关。
Front Immunol. 2021 Jun 14;12:684014. doi: 10.3389/fimmu.2021.684014. eCollection 2021.
4
Immune responses and residual SARS-CoV-2 in two critically ill COVID-19 patients before and after lung transplantation.两名危重症新冠肺炎患者肺移植前后的免疫反应及残余严重急性呼吸综合征冠状病毒2
J Infect. 2021 Apr;82(4):84-123. doi: 10.1016/j.jinf.2020.11.006. Epub 2020 Nov 12.
5
CD4 T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein.前列腺癌患者的 CD4 T 细胞对源自 SARS-CoV-2 刺突糖蛋白的抗原的免疫反应降低。
Front Immunol. 2021 May 3;12:629102. doi: 10.3389/fimmu.2021.629102. eCollection 2021.
6
Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients.SARS-CoV-2 疫苗接种的器官移植受者免疫反应缺陷的意义。
Sci Immunol. 2021 Jul 1;6(61). doi: 10.1126/sciimmunol.abj6513.
7
IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals.白细胞介素-33 在 COVID-19 恢复期个体中对 SARS-CoV-2 的反应与血清阳性相关。
Nat Commun. 2021 Apr 9;12(1):2133. doi: 10.1038/s41467-021-22449-w.
8
Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.COVID-19 患者体内的 SARS-CoV-2 与抗体反应的长期共存。
J Med Virol. 2020 Sep;92(9):1684-1689. doi: 10.1002/jmv.25946. Epub 2020 May 5.
9
Long-term infection of SARS-CoV-2 changed the body's immune status.新冠病毒长期感染改变了人体的免疫状态。
Clin Immunol. 2020 Sep;218:108524. doi: 10.1016/j.clim.2020.108524. Epub 2020 Jul 11.
10
Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.评估工作年龄段成年人的维生素 D 水平与 SARS-CoV-2 血清阳性之间的关联。
JAMA Netw Open. 2021 May 3;4(5):e2111634. doi: 10.1001/jamanetworkopen.2021.11634.

引用本文的文献

1
From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics.从自愿接种疫苗政策到癌症患者强制接种 COVID-19 疫苗：生物伦理学中的实证和跨学科研究。
BMC Med Ethics. 2022 Aug 28;23(1):88. doi: 10.1186/s12910-022-00827-3.
2
COVID-19 Vaccines and Immunosuppressed Patients With Cancer: Critical Considerations.COVID-19 疫苗和免疫抑制的癌症患者：关键考虑因素。
Clin J Oncol Nurs. 2022 Jul 25;26(4):367-373. doi: 10.1188/22.CJON.367-373.
3
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
实体瘤患者中mRNA抗SARS-CoV-2疫苗接种的疗效及体液免疫反应动态：来自意大利一家三级癌症中心机构登记处的结果
Ther Adv Med Oncol. 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687. eCollection 2022.
4
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study.COVID-19 疫苗在癌症患者中的疗效和安全性：一项前瞻性、多中心队列研究。
Future Oncol. 2022 Mar;18(10):1235-1244. doi: 10.2217/fon-2021-1248. Epub 2022 Jan 27.
5
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.预测 SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中的有效性的免疫生物标志物。
Blood Cancer J. 2021 Dec 14;11(12):202. doi: 10.1038/s41408-021-00594-1.
6
Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.癌症患者中导致 SARS-CoV-2 感染不良结局的免疫机制。
Transl Res. 2022 Mar;241:83-95. doi: 10.1016/j.trsl.2021.12.001. Epub 2021 Dec 3.
7
Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain.癌症与 2019 年冠状病毒病诊断、住院和死亡的风险：一项包括西班牙加泰罗尼亚 4618377 名成年人的基于人群的多州队列研究。
Int J Cancer. 2022 Mar 1;150(5):782-794. doi: 10.1002/ijc.33846. Epub 2021 Nov 3.
8
Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.癌症还是 COVID-19？癌症患者 COVID-19 疫苗接种建议的综述。
Curr Treat Options Oncol. 2021 Sep 13;22(10):95. doi: 10.1007/s11864-021-00903-7.